The role of angiopoietins as potential therapeutic targets in renal cell carcinoma.
Angiopoietin 2 (Ang2) is a secreted glycoprotein upregulated at sites of angiogenesis and has been implicated in cancer neovascularization. Recent studies have suggested efficacy of combined Ang and vascular endothelial growth factor receptor (VEGFR) inhibition for patients with metastatic renal cell carcinoma (mRCC). We measured Ang2 expression in human tissue and plasma, and tested the effect of dual Ang1/2 (trebananib; AMG386) or Ang2 alone (L1-7) inhibition with VEGFR inhibition on murine RCC growth and blood flow. Ang2 levels were higher in human tumors than normal tissues with RCC ranking highest for Ang2 expression across all tumor types tested. Plasma Ang2 was significantly higher in patients with mRCC compared to controls or patients with stage I disease. Plasma Ang2 decreased with sunitinib treatment and increased at time of disease progression. In the RCC mouse, dual Ang1/2 and Ang2 inhibition improved the activity of sunitinib. Combined Ang1/2 and VEGFR inhibition prevented the resumption of blood flow associated with sunitinib resistance. Thus, Ang2 inhibition, independent of Ang1 inhibition, improves the activity of sunitinib and plasma Ang2 increases in the setting of progression on sunitinib possibly contributing to resistance. Further, arterial spin-labeled perfusion magnetic resonance imaging might be a non-invasive marker of the antiangiogenic activity of Ang inhibitors.
Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Xiaoen
X
Wang
Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Andrea J
AJ
Bullock
Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Liang
L
Zhang
Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Lin
L
Wei
Oncology Research, Amgen Inc, Thousand Oaks, CA.
Dongyin
D
Yu
Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Kedar
K
Mahagaokar
Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
David C
DC
Alsop
Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
James W
JW
Mier
Departments of Oncology and Medicine, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.
Michael B
MB
Atkins
Oncology Research, Amgen Inc, Thousand Oaks, CA.
Angela
A
Coxon
Oncology Research, Amgen Inc, Thousand Oaks, CA.
Jon
J
Oliner
Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Rupal S
RS
Bhatt